Abstract
Circulating tumor DNA analysis holds promise for early detection of cancer. However, costs and complexity of genomic methods, and logistical requirements for blood collection and processing limit large scale implementation. Here, we evaluated the feasibility of genome-wide analysis of fragmentation patterns in plasma DNA obtained from dried blood spots (DBS). Across 75 individuals including 25 patients with cancer, we prepared conventional DBS, and plasma-separating DBS (psDBS) from whole blood samples, prior to plasma separation. In paired comparisons of plasma DNA between psDBS and blood tubes, we observed correlated concentrations, similar distributions of fragment lengths, correlated genome-wide fragmentation features, and equivalent performance of machine learning algorithms for cancer detection. Our results provide proof-of-principle that plasma DNA fragmentation analysis can be performed from small amounts of DNA obtained from psDBS. With further development and validation, this approach can expand the reach and impact of blood-based early cancer detection, particularly for resource constrained environments such as low- and middle-income countries and rural healthcare systems.
Competing Interest Statement
MDS, BRM, and MM are co-inventors on pending patent applications for methods of plasma DNA analysis evaluated in this study. MM consults for the Translational Genomics Research Institute, a not-for-profit research institution. All other authors declare that they have no competing interests.
Funding Statement
This study was funded by National Institutes of Health/National Cancer Institute grants U01CA243078, R01CA223481, P30CA014520 and P30CA014520-48S4.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Wisconsin-Madison gave ethical approval for this work (2016-0934). Western Institutional Review Board used by Translational Genomics Research Institute gave ethical approval for this work (20181812).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and materials availability
Genome sequencing data reported here will deposited in dbGaP upon acceptance. Code reproducing the reported analysis will be deposited to zenodo upon acceptance.
